| Identification | Back Directory | [Name]
2-Butenoic acid, 4-(4-bromophenyl)-4-oxo-, (5R,5aR,8aR,9R)-5,5a,6,8,8a,9-hexahydro-8-oxo-9-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl ester, (2E)- | [CAS]
2684412-41-5 | [Synonyms]
PI3K/AKT-IN-2
2-Butenoic acid, 4-(4-bromophenyl)-4-oxo-, (5R,5aR,8aR,9R)-5,5a,6,8,8a,9-hexahydro-8-oxo-9-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl ester, (2E)- | [Molecular Formula]
C32H27BrO10 | [MOL File]
2684412-41-5.mol | [Molecular Weight]
651.45 |
| Hazard Information | Back Directory | [Uses]
PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin[1]. | [IC 50]
MMP-2 | [References]
[1] Sun W, et al. Design, semi-synthesis and bioactivity evaluation of novel podophyllotoxin derivatives as potent anti-tumor agents. Bioorg Chem. 2022 May 26;126:105906. DOI:10.1016/j.bioorg.2022.105906 |
|
|